Market Research Report

Herceptin (Trastuzumab) and Biosimilar Market, Global Outlook and Forecast 2023-2029

  • AMR ID : 7-3284
  • CAT ID : 7
  • Pages : 115
  • Date : Jun 2023
 

The global Herceptin (Trastuzumab) and Biosimilar market was valued at US$ 4642.6 million in 2022 and is projected to reach US$ 6357.7 million by 2029, at a CAGR of 4.6% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Brand Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Herceptin (Trastuzumab) and Biosimilar include Roche, Amgen, Pfizer, Organon, Teva and Viatris, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer.
This report aims to provide a comprehensive presentation of the global market for Herceptin (Trastuzumab) and Biosimilar, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Herceptin (Trastuzumab) and Biosimilar. This report contains market size and forecasts of Herceptin (Trastuzumab) and Biosimilar in global, including the following market information:
Global Herceptin (Trastuzumab) and Biosimilar Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Herceptin (Trastuzumab) and Biosimilar Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Herceptin (Trastuzumab) and Biosimilar companies in 2022 (%)
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Herceptin (Trastuzumab) and Biosimilar manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Herceptin (Trastuzumab) and Biosimilar Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Herceptin (Trastuzumab) and Biosimilar Market Segment Percentages, by Type, 2022 (%)
Brand
Biosimilar
Global Herceptin (Trastuzumab) and Biosimilar Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Herceptin (Trastuzumab) and Biosimilar Market Segment Percentages, by Application, 2022 (%)
Breast Cancer
Stomach Cancer
Global Herceptin (Trastuzumab) and Biosimilar Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Herceptin (Trastuzumab) and Biosimilar Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Herceptin (Trastuzumab) and Biosimilar revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Herceptin (Trastuzumab) and Biosimilar revenues share in global market, 2022 (%)
Key companies Herceptin (Trastuzumab) and Biosimilar sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Herceptin (Trastuzumab) and Biosimilar sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
Amgen
Pfizer
Organon
Teva
Viatris
Outline of Major Chapters:
Chapter 1: Introduces the definition of Herceptin (Trastuzumab) and Biosimilar, market overview.
Chapter 2: Global Herceptin (Trastuzumab) and Biosimilar market size in revenue and volume.
Chapter 3: Detailed analysis of Herceptin (Trastuzumab) and Biosimilar manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Herceptin (Trastuzumab) and Biosimilar in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Herceptin (Trastuzumab) and Biosimilar capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

1 Introduction to Research & Analysis Reports
1.1 Herceptin (Trastuzumab) and Biosimilar Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Herceptin (Trastuzumab) and Biosimilar Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Herceptin (Trastuzumab) and Biosimilar Overall Market Size
2.1 Global Herceptin (Trastuzumab) and Biosimilar Market Size: 2022 VS 2029
2.2 Global Herceptin (Trastuzumab) and Biosimilar Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Herceptin (Trastuzumab) and Biosimilar Sales: 2018-2029
3 Company Landscape
3.1 Top Herceptin (Trastuzumab) and Biosimilar Players in Global Market
3.2 Top Global Herceptin (Trastuzumab) and Biosimilar Companies Ranked by Revenue
3.3 Global Herceptin (Trastuzumab) and Biosimilar Revenue by Companies
3.4 Global Herceptin (Trastuzumab) and Biosimilar Sales by Companies
3.5 Global Herceptin (Trastuzumab) and Biosimilar Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Herceptin (Trastuzumab) and Biosimilar Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Herceptin (Trastuzumab) and Biosimilar Product Type
3.8 Tier 1, Tier 2 and Tier 3 Herceptin (Trastuzumab) and Biosimilar Players in Global Market
3.8.1 List of Global Tier 1 Herceptin (Trastuzumab) and Biosimilar Companies
3.8.2 List of Global Tier 2 and Tier 3 Herceptin (Trastuzumab) and Biosimilar Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Herceptin (Trastuzumab) and Biosimilar Market Size Markets, 2022 & 2029
4.1.2 Brand
4.1.3 Biosimilar
4.2 By Type - Global Herceptin (Trastuzumab) and Biosimilar Revenue & Forecasts
4.2.1 By Type - Global Herceptin (Trastuzumab) and Biosimilar Revenue, 2018-2023
4.2.2 By Type - Global Herceptin (Trastuzumab) and Biosimilar Revenue, 2024-2029
4.2.3 By Type - Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share, 2018-2029
4.3 By Type - Global Herceptin (Trastuzumab) and Biosimilar Sales & Forecasts
4.3.1 By Type - Global Herceptin (Trastuzumab) and Biosimilar Sales, 2018-2023
4.3.2 By Type - Global Herceptin (Trastuzumab) and Biosimilar Sales, 2024-2029
4.3.3 By Type - Global Herceptin (Trastuzumab) and Biosimilar Sales Market Share, 2018-2029
4.4 By Type - Global Herceptin (Trastuzumab) and Biosimilar Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Herceptin (Trastuzumab) and Biosimilar Market Size, 2022 & 2029
5.1.2 Breast Cancer
5.1.3 Stomach Cancer
5.2 By Application - Global Herceptin (Trastuzumab) and Biosimilar Revenue & Forecasts
5.2.1 By Application - Global Herceptin (Trastuzumab) and Biosimilar Revenue, 2018-2023
5.2.2 By Application - Global Herceptin (Trastuzumab) and Biosimilar Revenue, 2024-2029
5.2.3 By Application - Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share, 2018-2029
5.3 By Application - Global Herceptin (Trastuzumab) and Biosimilar Sales & Forecasts
5.3.1 By Application - Global Herceptin (Trastuzumab) and Biosimilar Sales, 2018-2023
5.3.2 By Application - Global Herceptin (Trastuzumab) and Biosimilar Sales, 2024-2029
5.3.3 By Application - Global Herceptin (Trastuzumab) and Biosimilar Sales Market Share, 2018-2029
5.4 By Application - Global Herceptin (Trastuzumab) and Biosimilar Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region - Global Herceptin (Trastuzumab) and Biosimilar Market Size, 2022 & 2029
6.2 By Region - Global Herceptin (Trastuzumab) and Biosimilar Revenue & Forecasts
6.2.1 By Region - Global Herceptin (Trastuzumab) and Biosimilar Revenue, 2018-2023
6.2.2 By Region - Global Herceptin (Trastuzumab) and Biosimilar Revenue, 2024-2029
6.2.3 By Region - Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share, 2018-2029
6.3 By Region - Global Herceptin (Trastuzumab) and Biosimilar Sales & Forecasts
6.3.1 By Region - Global Herceptin (Trastuzumab) and Biosimilar Sales, 2018-2023
6.3.2 By Region - Global Herceptin (Trastuzumab) and Biosimilar Sales, 2024-2029
6.3.3 By Region - Global Herceptin (Trastuzumab) and Biosimilar Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country - North America Herceptin (Trastuzumab) and Biosimilar Revenue, 2018-2029
6.4.2 By Country - North America Herceptin (Trastuzumab) and Biosimilar Sales, 2018-2029
6.4.3 US Herceptin (Trastuzumab) and Biosimilar Market Size, 2018-2029
6.4.4 Canada Herceptin (Trastuzumab) and Biosimilar Market Size, 2018-2029
6.4.5 Mexico Herceptin (Trastuzumab) and Biosimilar Market Size, 2018-2029
6.5 Europe
6.5.1 By Country - Europe Herceptin (Trastuzumab) and Biosimilar Revenue, 2018-2029
6.5.2 By Country - Europe Herceptin (Trastuzumab) and Biosimilar Sales, 2018-2029
6.5.3 Germany Herceptin (Trastuzumab) and Biosimilar Market Size, 2018-2029
6.5.4 France Herceptin (Trastuzumab) and Biosimilar Market Size, 2018-2029
6.5.5 U.K. Herceptin (Trastuzumab) and Biosimilar Market Size, 2018-2029
6.5.6 Italy Herceptin (Trastuzumab) and Biosimilar Market Size, 2018-2029
6.5.7 Russia Herceptin (Trastuzumab) and Biosimilar Market Size, 2018-2029
6.5.8 Nordic Countries Herceptin (Trastuzumab) and Biosimilar Market Size, 2018-2029
6.5.9 Benelux Herceptin (Trastuzumab) and Biosimilar Market Size, 2018-2029
6.6 Asia
6.6.1 By Region - Asia Herceptin (Trastuzumab) and Biosimilar Revenue, 2018-2029
6.6.2 By Region - Asia Herceptin (Trastuzumab) and Biosimilar Sales, 2018-2029
6.6.3 China Herceptin (Trastuzumab) and Biosimilar Market Size, 2018-2029
6.6.4 Japan Herceptin (Trastuzumab) and Biosimilar Market Size, 2018-2029
6.6.5 South Korea Herceptin (Trastuzumab) and Biosimilar Market Size, 2018-2029
6.6.6 Southeast Asia Herceptin (Trastuzumab) and Biosimilar Market Size, 2018-2029
6.6.7 India Herceptin (Trastuzumab) and Biosimilar Market Size, 2018-2029
6.7 South America
6.7.1 By Country - South America Herceptin (Trastuzumab) and Biosimilar Revenue, 2018-2029
6.7.2 By Country - South America Herceptin (Trastuzumab) and Biosimilar Sales, 2018-2029
6.7.3 Brazil Herceptin (Trastuzumab) and Biosimilar Market Size, 2018-2029
6.7.4 Argentina Herceptin (Trastuzumab) and Biosimilar Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Revenue, 2018-2029
6.8.2 By Country - Middle East & Africa Herceptin (Trastuzumab) and Biosimilar Sales, 2018-2029
6.8.3 Turkey Herceptin (Trastuzumab) and Biosimilar Market Size, 2018-2029
6.8.4 Israel Herceptin (Trastuzumab) and Biosimilar Market Size, 2018-2029
6.8.5 Saudi Arabia Herceptin (Trastuzumab) and Biosimilar Market Size, 2018-2029
6.8.6 UAE Herceptin (Trastuzumab) and Biosimilar Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Roche
7.1.1 Roche Company Summary
7.1.2 Roche Business Overview
7.1.3 Roche Herceptin (Trastuzumab) and Biosimilar Major Product Offerings
7.1.4 Roche Herceptin (Trastuzumab) and Biosimilar Sales and Revenue in Global (2018-2023)
7.1.5 Roche Key News & Latest Developments
7.2 Amgen
7.2.1 Amgen Company Summary
7.2.2 Amgen Business Overview
7.2.3 Amgen Herceptin (Trastuzumab) and Biosimilar Major Product Offerings
7.2.4 Amgen Herceptin (Trastuzumab) and Biosimilar Sales and Revenue in Global (2018-2023)
7.2.5 Amgen Key News & Latest Developments
7.3 Pfizer
7.3.1 Pfizer Company Summary
7.3.2 Pfizer Business Overview
7.3.3 Pfizer Herceptin (Trastuzumab) and Biosimilar Major Product Offerings
7.3.4 Pfizer Herceptin (Trastuzumab) and Biosimilar Sales and Revenue in Global (2018-2023)
7.3.5 Pfizer Key News & Latest Developments
7.4 Organon
7.4.1 Organon Company Summary
7.4.2 Organon Business Overview
7.4.3 Organon Herceptin (Trastuzumab) and Biosimilar Major Product Offerings
7.4.4 Organon Herceptin (Trastuzumab) and Biosimilar Sales and Revenue in Global (2018-2023)
7.4.5 Organon Key News & Latest Developments
7.5 Teva
7.5.1 Teva Company Summary
7.5.2 Teva Business Overview
7.5.3 Teva Herceptin (Trastuzumab) and Biosimilar Major Product Offerings
7.5.4 Teva Herceptin (Trastuzumab) and Biosimilar Sales and Revenue in Global (2018-2023)
7.5.5 Teva Key News & Latest Developments
7.6 Viatris
7.6.1 Viatris Company Summary
7.6.2 Viatris Business Overview
7.6.3 Viatris Herceptin (Trastuzumab) and Biosimilar Major Product Offerings
7.6.4 Viatris Herceptin (Trastuzumab) and Biosimilar Sales and Revenue in Global (2018-2023)
7.6.5 Viatris Key News & Latest Developments
8 Global Herceptin (Trastuzumab) and Biosimilar Production Capacity, Analysis
8.1 Global Herceptin (Trastuzumab) and Biosimilar Production Capacity, 2018-2029
8.2 Herceptin (Trastuzumab) and Biosimilar Production Capacity of Key Manufacturers in Global Market
8.3 Global Herceptin (Trastuzumab) and Biosimilar Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Herceptin (Trastuzumab) and Biosimilar Supply Chain Analysis
10.1 Herceptin (Trastuzumab) and Biosimilar Industry Value Chain
10.2 Herceptin (Trastuzumab) and Biosimilar Upstream Market
10.3 Herceptin (Trastuzumab) and Biosimilar Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Herceptin (Trastuzumab) and Biosimilar Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

 
Choose License Type

Single User : $3250


Corporate User : $4225


Why Choose Us ?

24/7 Research support

Quality assurance

Information security

Frequently Asked Questions

The report efficiently evaluates the market from various dimensions to deliver an end-product that is informative, elaborate, and accurate and includes detailed market segmentation, regional analysis, and competitive landscape of the industry.
The report efficiently evaluates the current market size and provides industry forecast. The market was valued at xx Million US$ in 2019, and is expected to grow at a CAGR of xx% during the period 2020-2027.
The report efficiently evaluates the current market size and provides forecast for the industry in terms of Value (US$ Mn) and Volume (Thousands Units).
Market is segmented by Types, Applications, Technology, End-use Industries, and Regions.
The report presents the current market size, and market forecast, market opportunities, key drivers and restraints, regulatory scenario, industry trend, PESTLE analysis, PORTER’s analysis, new product approvals/launch, promotion and marketing initiatives, pricing analysis, competitive landscape which help businesses in decision making. The analysis data is based on current and historical market trends which help in investment related decisions.
Custom research is crucial components of the business strategy which helps any organization to gain insight into specific business sector, aligned with specific area of interest. Thus, SMI offers more accurate, pragmatic, and actionable information specifically tailored to suit your business needs.

Subscribe Newsletter

  Subscribe